Flatiron Health is a healthcare generation and facility company whose goal is to accelerate cancer studies and provide better patient care. Your Flatiron Assist is an oncology-specific clinical resolution support platform that provides clinicians with information about point-of-care treatments through a resolution aid tool built into the EHR.
The company will build on its success by announcing earlier this week a partnership with the Medical University of South Carolina (MUSC) to offer Flatiron Assist to oncology physicians at MUSC Hollings Cancer Center.
“Flatiron and MUSC have a common goal: to leverage technology, particularly Flatiron Assist, for cancer care, create a more equitable health care system, and drive positive patient outcomes and insights for oncology physicians at MUSC Hollings Cancer Center,” James Hamrick, MD, vice president of clinical oncology at Flatiron Health, told VatorNews.
“Flatiron and MUSC are committed to providing better care for cancer patients, equipping care providers and physicians with equipment to drive positive patient outcomes, and offering equitable access to state-of-the-art treatments.
The collaboration between Flatiron Health and MUSC will provide clinicians with complex information about cancer care through Flatiron Assist, which will be incorporated directly with MUSC’s Epic EHR and presented to clinicians at the point of care. Flatiron Assist features NCCN guidelines, clinical research, and site-specific personal tastes directly into the EHR to help physicians make medication prescribing decisions.
“Partnering with the Medical University of South Carolina Hollings Cancer Center gives us the opportunity to advance our shared vision to provide more standardized, effective and efficient cancer care,” Hamrick said.
Currently, Flatiron Assist has more than 700 medical oncologist users and has been leveraged in more than 90,000 remedy decisions. It showed 88% agreement with NCCN rules and 85% use of the site’s preferred remedy regimens. Flatiron Assist users also adopt new treatments on average. 59 days earlier than non-Flatiron Assist users.
“Flatiron Assist will streamline administrative and pharmaceutical workflows, monetary functionality, and patient outcomes at MUSC. This clinical resolution aid tool will also help standardize the quality of care among providers, enabling faster, more efficient, and more equitable care for cancer patients. Hamrick explained.
For Flatiron, the good fortune of the partnership with MUSC is explained by the widespread adoption and satisfaction of Flatiron Assist among MUSC’s medical oncologists, he said.
“Flatiron Assist will introduce new features and use cases to help and have an effect on the evolution of the generation in cancer care at MUSC, with the ultimate goal of having an effect on patient outcomes.